ATG7抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using ATG7 mouse mAb (green) and negative control (red).    

  
  

ATG7 (Autophagy-related protein 7) is a critical enzyme in the autophagy pathway, a conserved cellular process responsible for degrading damaged organelles, misfolded proteins, and pathogens. As an E1-like ubiquitin-activating enzyme, ATG7 catalyzes the conjugation of ATG12 to ATG5 and the lipidation of microtubule-associated protein 1 light chain 3 (LC3), both essential steps in autophagosome formation. Dysregulation of ATG7-mediated autophagy is linked to various diseases, including cancer, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), and infectious diseases.

ATG7 antibodies are widely used tools in autophagy research to detect ATG7 protein expression, localization, and activity. These antibodies enable the study of autophagy dynamics through techniques like Western blotting, immunofluorescence, and immunohistochemistry. Monoclonal and polyclonal variants are available, often validated for specificity in human, mouse, or rat samples. Researchers rely on ATG7 antibodies to investigate autophagy's role in cellular stress responses, disease mechanisms, or therapeutic interventions.

Validating ATG7 antibodies requires careful controls, such as using ATG7-knockout cell lines, to confirm target specificity. Given the therapeutic potential of modulating autophagy, ATG7 antibodies also aid in drug discovery, serving as biomarkers for autophagy activity or targets in diseases where autophagy is impaired. Their application spans basic research, clinical diagnostics, and preclinical studies.